- Eli Lilly announced positive topline results from its TRIUMPH clinical trial program for retatrutide, a weekly injection that activates three hormone receptors, leading to significant weight loss and improved blood sugar control.
- In the TRIUMPH-2 trial with participants who had type-2 diabetes and obesity, the highest dose of retatrutide resulted in an average weight loss of 50 lbs (20.8% of body weight) over 80 weeks, along with improved blood sugar control.
- In the TRIUMPH-3 trial with participants who had obesity and cardiovascular disease, the highest dose of retatrutide led to an average weight loss of 56 lbs (22.6% of body weight) over 80 weeks, as well as improvements in heart disease risk markers such as triglycerides, waist circumference, blood pressure, and inflammation markers.
Retatrutide just took a major step in its journey toward FDA approval. Eli Lilly, the company that makes retatrutide, announced the topline results from its TRIUMPH clinical trial program
Retatrutide is a weekly injection that is slightly more sophisticated than other GLP-1 drugs because it is a “triple agonist.” Unlike current drugs (Zepbound, Ozempic-type medications) that target one or two hormone pathways, retatrutide activates three hormone receptors (GIP, GLP-1, and glucagon) at once
TRIUMPH had separate clinical trials: one in individuals with type-2 diabetes and obesity, and the other in non-diabetics with obesity and cardiovascular disease
Advertisement
TRIUMPH-2 featured about 1,150 participants with type-2 diabetes and obesity. At the highest dose (12 mg), participants lost an average of 50 lbs (20.8% of body weight) over 80 weeks. Blood sugar control (A1C) also improved significantly. A1C is a measure of blood sugar over a period of time, rather than an instantaneous reading, and shows more steady results
TRIUMPH-3 featured about 1,950 participants with obesity and cardiovascular disease. The highest dose led to an average loss of 56 lbs (22.6% of body weight) over 80 weeks. This is among the largest weight-loss results reported in a trial of this size. As for heart disease risk markers: triglycerides dropped 37%, waist circumference shrank about 7.5 inches, blood pressure and inflammation markers (hsCRP) also improved
These are the largest weight-loss results yet reported for an injectable obesity drug in trials this size, exceeding what’s typically seen with tirzepatide or semaglutide
If the name retatrutide or “reta” sounds familiar to you, this injection is popular among the biohacking/peptide community. If Lilly is able to get FDA approval (which it plans to attempt in Q1 of 2027), then it will certainly become more mainstream. FDA approval requires a number of things, which include but are not limited to: proving the drug is safe, proving it works for the intended purpose, and showing it can be manufactured at scale
Advertisement
It’s important to note that these are the topline results issuedtical analysis haven’t been published yet. The TRIUMPH results are encouraging, but there are still steps ahead before it becomes available
This story was originally published byMen’s Fitnesson Jul 24, 2026, where it first appeared in theNewssection. Add Men’s Fitness as aPreferred
